Nonenzymatic Posttranslational Modifications and Peptide Cleavages Observed in Peptide Epimers
Journal of the American Society for Mass Spectrometry · 2023
DOI: 10.1021/jasms.3c00092 ↗At a glance
Journal article in Journal of the American Society for Mass Spectrometry, 2023. Written by Connor C Long and 5 co-authors. Institution: Department of Biochemistry, Cellular, and Molecular Biology, University of Tennessee, Knoxville, Tennessee 37996, United States. Major MEDLINE topics: Aspartic Acid, Isoaspartic Acid. Cited 6 times so far (Crossref); 62 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (original language)
Posttranslational modifications (PTMs) play vital roles in cellular homeostasis and are implicated in various pathological conditions. This work uses two ion mobility spectrometry-mass spectrometry (IMS-MS) modalities, drift-tube IMS (DT-IMS) and trapped IMS (TIMS), to characterize three important nonenzymatic PTMs that induce no mass loss: l/d isomerization, aspartate/isoaspartate isomerization, and cis/trans proline isomerization. These PTMs are assessed in a single peptide system, the recently discovered pleurin peptides, Plrn2, from Aplysia californica. We determine that the DT-IMS-MS/MS can capture and locate asparagine deamidation into aspartate and its subsequent isomerization to isoaspartate, a key biomarker for age-related diseases. Additionally, nonenzymatic peptide cleavage via in-source fragmentation is evaluated for differences in the intensities and patterns of fragment peaks between these PTMs. Peptide fragments resulting from in-source fragmentation, preceded by peptide denaturation by liquid chromatography (LC) mobile phase, exhibited cis/trans proline isomerization. Finally, the effects of differing the fragmentation voltage at the source and solution-based denaturation conditions on in-source fragmentation profiles are evaluated, confirming that LC denaturation and in-source fragmentation profoundly impact N-terminal peptide bond cleavages of Plrn2 and the structures of their fragment ions. With that, LC-IMS-MS/MS coupled with in-source fragmentation could be a robust method to identify three important posttranslational modifications: l/d isomerization, Asn-deamidation leading to Asp/IsoAsp isomerization, and cis/trans proline isomerization.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry, Cellular, and Molecular Biology, University of Tennessee, Knoxville, Tennessee 37996, United States.
- Department of Chemistry, University of Tennessee, Knoxville, Tennessee 37996, United States.
- Department of Chemistry and the Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
ORCID profiles: Aleksandra Antevska, David H Mast, Samuel Okyem, Jonathan V Sweedler, Thanh D Do
Funding
- NIDA NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- University of Tennessee
- National Institute on Drug Abuse
- Agilent Technologies
- University of Tennessee, Knoxville
Cite
APA
Long, C. C., Antevska, A., Mast, D. H., Okyem, S., Sweedler, J. V., & Do, T. D. (2023). Nonenzymatic Posttranslational Modifications and Peptide Cleavages Observed in Peptide Epimers. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.3c00092
Vancouver
Long CC, Antevska A, Mast DH, Okyem S, Sweedler JV, Do TD. Nonenzymatic Posttranslational Modifications and Peptide Cleavages Observed in Peptide Epimers. Journal of the American Society for Mass Spectrometry. 2023. doi:10.1021/jasms.3c00092
BibTeX
@article{Long2023,
author = {Long, Connor C and Antevska, Aleksandra and Mast, David H and Okyem, Samuel and Sweedler, Jonathan V and Do, Thanh D},
title = {Nonenzymatic Posttranslational Modifications and Peptide Cleavages Observed in Peptide Epimers},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2023},
doi = {10.1021/jasms.3c00092}
}
EUVIMED